CombiMatrix Corporation Stockholders Approve Second Tranche of Series C Preferred Stock Financing
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
IRVINE, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer, announced today that its stockholders approved the sale of shares of the Company's Series C Preferred Stock associated with a second tranche of the equity financing that was originally announced on May 6, 2013. Upon closing the first tranche, the Company received gross proceeds of $1.2 million from the investors. The Company filed a proxy statement to seek stockholder approval to raise the remaining $1.2 million, which approval was obtained at the Company's annual meeting of stockholders held on June 27, 2013.
Help employers find you! Check out all the jobs and post your resume.
IRVINE, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer, announced today that its stockholders approved the sale of shares of the Company's Series C Preferred Stock associated with a second tranche of the equity financing that was originally announced on May 6, 2013. Upon closing the first tranche, the Company received gross proceeds of $1.2 million from the investors. The Company filed a proxy statement to seek stockholder approval to raise the remaining $1.2 million, which approval was obtained at the Company's annual meeting of stockholders held on June 27, 2013.
Help employers find you! Check out all the jobs and post your resume.